Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical is positioned to benefit from a compelling adoption thesis built on the LIBERTY system’s FDA-cleared, single-use robotic platform, which directly addresses the American Medical Association’s end-2025 public policy on occupational radiation exposure and specialty-society concerns about lead-apron strain. The company’s early traction during LMR across multiple healthcare systems, including Emory Healthcare, suggests a shorter sales cycle than traditional robots, while the account base of roughly 85 units sold through 1H26 across 10 to 11 accounts indicates room for utilization to deepen as operators progress through seven to ten cases and do not revert. Although 3Q26 and 4Q26 revenue are modeled at $400K and $600K and margin expansion is delayed, the expected cost-of-revenue improvement, broader U.S. territory rollout, and international clearances support a durable longer-term growth and gross-margin inflection.

Microbot Medical is a development-stage company with no prior revenue history, so its shift to commercial operations carries substantial execution risk, especially since success will depend on salesforce deployment, physician training, and support infrastructure. Manufacturing is concentrated entirely through contract partners in Israel, leaving the business exposed to geopolitical instability, supply chain disruptions, and product quality issues that could impair commercial demand, while expansion into coronary and neurovascular uses would require new regulatory submissions and uncertain clinical timelines. Although it has raised capital and expects a 24- to 36-month runway, monthly cash burn is set to rise significantly as commercialization scales, and any reimbursement changes or slower-than-anticipated adoption could hinder breakeven and raise dilution risk.